Related Experiment Videos
Topoisomerase-I inhibitors in gynaecologic tumours
C F Verschraegen1, A P Kudelka, J J Kavanagh
1Section of Gynecologic Medical Oncology, M D Anderson Cancer Center, Houston, TX 77030, USA. cverschr@notes.mdacc.tmc.edu
Annals of the Academy of Medicine, Singapore
|January 27, 1999
Abstract:
Topoisomerase inhibitors have been studied using various dose schedules in the treatment of refractory or recurrent gynaecologic cancers. Response rates are between 13% and 20%. Main toxic effects are haematologic and gastrointestinal. The latter remains problematic. Radiotherapy, alkylate, platinum analogs and topoisomerase II inhibitors are currently being studied in combination with camptothecins.